Safety and Efficacy Evaluation Using Nonhuman Primates - Nonhuman Primates in Biomedical Research - page 499

Dixit, R., & Boelsterli, U. A. (2007). Healthy animals and animal models
of human disease(s) in safety assessment of human pharmaceuticals,
including therapeutic

Guidance for Industry. Safety Testing of Drug Metabolites. (2008). Food
and Drug Administration (FDA). Center for Drug Evaluation and
Research (CDER). February.
Hardisty, J. F., Anderson, D. C., Brodie, S., Cline, J. M., Hahn, F. F.,
Kolend-Roberts, H., et al. (2008). Histopathology of the urinary
bladder if cynomolgus monkeys treated with PPAR agonists. Toxicol.
Pathol., 36, 769 e 776.
Henck, J. W., Hilbish, K. G., Serabian, M. A., Cavagnaro, J. A.,
Hendrickx, A. G., Agnish, N. D., et al. (1996). Reproductive toxicity
testing of therapeutic biotechnology agents. Teratology, 53, 185 e 195.
Hendrie, T., Peterson, P., Short, J., Tarantal, A., Rothgarn, E.,
Hendrie, M., et al. (1996). Frequency of prenatal loss in a macaque
breeding colony. Am. J. Primatol., 40,41 e 53.
Henriques, T. A., Beck, T. W., Douglas, C. L., Jones, H. M., Kremer, J. J.,
Kruzich, P. J., et al. (2010). Left thorocotomy surgical approach for
chronic instrumentation in dogs and monkeys providing high-quality
electrocardiogram signals.

antibodies. Drug Discovery Today, 12,

336 e 342.
Dulichand, R., & Dureja, H. (2010). New Drug Approval Process:
regulatory view. Latest reviews 8. < http://www.pharmainfo.net/
reviews/new-drug-approval-process-regulatory-view > Accessed

10.15.11.
EFPIA Briefing Paper. (2004). The Use of Non-Human Primates by the
Pharmaceutical Industry in Europe. European Federation of Phar-
maceutical Industries and Associations (EFPIA).
EFPIA Briefing Paper. (2008). Why Non-human Primates are Needed for
Researching Monoclonal Antibodies. European Federation of Phar-
maceutical Industries and Associations (EFPIA).
Evron, T., Moyal-Segal, L. B., Lamm, N., Geffen, A., & Soreq, H. (2005).
RNA-targeted suppression of stress-induced allostasis in primate
spinal cord neurons. Neurodegen. Dis., 2,16 e 27.
Food andDrugAdministration (FDA). (2009). Drugs: therapeutic biological
applications (BLA). < http://www.fda.gov/Drugs/Development
ApprovalProcess/HowDrugsareDevelopedandApproved/Approval
Applications/TherapeuticBiologicApplications/default.htm >
Accessed 10.15.11.
Food andDrugAdministration (FDA). (2010). Drugs: newdrug applications
(NDA). < http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandApproved/ApprovalApplications/
NewDrugApplicationNDA/default.htm

J. Pharmacol. Toxicol. Meth., 62,

136 e 142.
Hoivik, D. J., Qualls, C. W., Mirabile, R. C., Cariello, N. F.,
Kimbrough, C. L., Colton, H. M., et al. (2004). Fibrates induce
hepatic peroxisome and mitochondrial proliferation without overt
evidence of cellular proliferation and oxidative stress in cynomolgus
monkeys. Carcinogenesis, 25, 1757 e 1769.
International Conference on Harmonisation (ICH). (1997). Guidance for
Industry S6: preclinical safety evaluation of biotechnology-derived
pharmaceuticals. Food and Drug Administration. 62 FR 61515,
November 1997.
International Conference on Harmonisation (ICH). (1998). Guideline S4:
duration of chronic toxicity testing in animals (rodent and non rodent
toxicity testing). International Council on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals for Human
Use. September.
International Conference on Harmonisation (ICH). (2000). Guideline
S7A: safety pharmacology studies for human pharmaceuticals.
International Council on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use. November.
International Conference on Harmonisation (ICH). (2005). Guideline
S7B: the non-clinical evaluation of the potential for delayed
ventricular repolarization (QT interval prolongation) by human
pharmaceuticals. International Council on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals for Human
Use. May.
International Conference on Harmonisation (ICH). (2009). Addendum to
ICH S6 (R1): preclinical safety evaluations of biotechnology-derived
pharmaceuticals. International Council on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals for Human
Use. October.
International Conference on Harmonisation (ICH). (2010). Guidance for
Industry M3 (R2): nonclinical safety studies for the conduct of human
clinical

Accessed 10.15.11.
Food and Drug Administration (FDA). (2011). Drugs: investigational new
drug applications (IND).

>

http://www.fda.gov/Drugs/Development
ApprovalProcess/HowDrugsareDevelopedandApproved/Approval
Applications/InvestigationalNewDrugINDApplication/default.htm >
Accessed 10.15.11.
Frings, W., & Cavagnaro, J. A. (2005). Predicted clinical immuno-
genicity: intended or unintended. In G. F. Weinbauer, E. Buse,
W. M¨ ller & F. Vogel (Eds.), New Developments and Challenges in
Primate Toxicology (pp. 9 e 21). New York: Waxmann Verlag.
Fuchs, A., & Weinbauer, G. F. (2006). Feasibility of embryofetal devel-
opment studies in the marmoset (Callithrix jacchus). In
G. F. Weinbauer & F. Vogel (Eds.), Novel Approaches Towards
Primate Toxicology (pp. 10 e 122). Muenster: Waxmann Publisher.
Gale, E. A. (2001). Lessons from glitazones: a story of drug development.
Lancet., 357, 1870 e 1875.
Gauvin, D. V., & Baird, T. J. (2008). A functional observational battery in
non-human primates for regulatory-required neurobehavioral assess-
ments. J. Pharmacol. Toxicol. Meth., 58,88 e 93.
Glaesner, W., Vick, A. M., Millican, R., Ellis, B., Tschang, S. H., Tian, Y.,
et al. (2010). Engineering and characterization of the long-acting
glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Diabetes/Metab. Res. Rev., 26, 287 e 296.
Green, M. D., & Hartsough, M. (2008). In J. A. Cavagnaro (Ed.),
Preclinical Safety Evaluation of Biopharmaceuticals: a science based
approach to facilitating clinical trials (pp. 277

<

trials and marketing authorization for pharmaceuticals.

292). Hoboken: John January.

Ingram, D. K., Nakamura, E., Smucny, D., Roth, G. S., & Lane, M. A.
(2001). Strategy for identifying biomarkers of aging in long-lived
species. Exp. Gerontol., 36, 1025 e 1034.
Iwamoto, J., Seki, A., Matsuura, M., Sato, Y., Takeda, T., Matsumoto, H.,
et al. (2009). Influence of ovariectomy on bone turnover and
trabecular bone mass in mature cynomolgus monkeys. Yonsei Med. J.,
40, 358 e 367.

e

Wiley & Sons.
Golub, M. S. (1990). Use of monkey neonatal neurobehavioral test
batteries in safety testing protocols. Neurotoxicol. Teratol., 12,
537 e 541.
Guidance for Industry. Nonclinical Safety Evaluation of Pediatric Drug
Products. (2006). Food and Drug Administration (FDA). Center for
Drug Evaluation and Research (CDER). February.